Fig 1.
Identifies two clusters with distinct survival outcomes, showing that upregulated pathways in Cluster 2 are linked to poorer prognosis.
(A) Consensus matrix (k = 2) shows two clusters. (B) Scatter plot differentiates Cluster 1 (red) and Cluster 2 (blue). (C) Kaplan-Meier curves indicate Cluster 2 has poorer prognosis (p = 0.021). (D) GSEA heatmap for Hallmark gene sets correlates Cluster 2 with worse survival. (E) GSEA heatmap for KEGG gene sets shows enriched pathways. (F) Bar chart indicates higher Hallmark pathway enrichment in Cluster 2. (G) Scatter plot highlights KEGG pathway enrichment in Cluster 2 and survival outcomes. (H) The histogram shows the impact of the PTPN family on Cluster1 and Cluster2 through random forest.
Fig 2.
Analysis of Immune Infiltration and PTPN Gene Expression in Clusters 1 and 2.
(A-D) Boxplots show differential expression of immune markers and enrichment scores between Cluster 1 (red) and Cluster 2 (blue). Significance: *p < 0.05, **p < 0.01, ***p < 0.001. (E) Correlation heatmap of immune infiltration types (CIBERSORT and Quantiseq) vs. PTPN family genes. (F) Enrichment scatter plot of immune cell types vs. enrichment levels.
Fig 3.
Analysis of Cellular Heterogeneity and Differential Gene Expression in Active and Inactive Groups.
(A) tSNE plot show 10 cellular clusters by cell type. (B) Heatmap of marker gene expression across clusters. (C) The bar chart illustrates that at an AUC threshold of 0.022, 13,402 cells were identified as Active using AUCell. (D) tSNE plot differentiating Active (blue) and Inactive (yellow) groups. (E) Stacked bar chart of cellular subset proportions in Active and Inactive groups. (F) The volcano plots of different cell types illustrate the differentially expressed genes (DEGs) between the Active and Inactive groups. (G) Volcano plots of differentially expressed genes (DEGs) between Active and Inactive groups were generated based on pseudobulks. (H) Dot plots of Hallmark gene set enrichment analysis.
Fig 4.
Analysis of CD4+ T Cell Subpopulations and Functional States in Active and Inactive Groups.
(A) tSNE plot of CD4+ T cell subsets: Tn, Tm, and Treg.(B) Stacked bar charts showing CD4+ T cell subset proportions between Active and Inactive groups. (C) Scatter plot of CD4+ T cell trajectories from Monocle2 by subtype and pseudotime. (D) Scatter plot of PTPN gene expression across CD4+ T cell subsets along pseudotime. (E) Enrichment scatter plot of pathway changes in TNFRSF9+ Treg cells between groups. (F) Enrichment scatter plot of transcriptional regulators in the TNFA_signaling_via_NFkB pathway for Treg cells.
Fig 5.
Characterization and Functional Analysis of CD8 + T Cell Subsets in Active and Inactive Groups.
(A) tSNE plot of CD8+ T cell subsets.(B) Stacked bar charts of CD8+ T cell subset proportions between Active and Inactive groups. (C) Scatter plot of CD8+ T cell pseudotime trajectory from Monocle2. (D) Scatter plot of PTPN gene expression dynamics across CD8+ T cells along pseudotime. (E) Enrichment scatter plot of pathway changes in Temra cells. (F) Enrichment scatter plot of transcriptional regulators in the Apoptosis pathway for Temra cells.
Fig 6.
Heterogeneity and Functional Trajectory of Mononuclear Phagocytes in Active and Inactive Groups.
(A) tSNE plot of mononuclear plagocyte subsets: monocytes,M1_TAM, and M2_TAM. (B) Stacked bar charts showing proportional changes of mononuclear phagocyte subsets between Active and Inactive groups. (C) Scatter plot of pseudotemporal trajectories of mononuclear phagocyte subsets from Monocle2. (D) Scatter plot of PTPN gene expression dynamics across mononuclear phagocyte subsets along the pseudotemporal trajectory. (E) Enrichment scatter plot of pathway changes in M2_TAM between Active and Inactive groups. (F) Enrichment scatter plot of transcriptional regulators in the E2F pathway for M2_TAM.
Fig 7.
Pan-Cancer Analysis of PTPN23 Expression and Its Associations with Clinical Outcomes and Immune Infiltration.
(A) PTPN23 mRNA expression across cancer types in TCGA. (B) PTPN23 expression comparison between normal and tumor samples in TCGA. (C) PTPN23 expression in normal (GTEx) vs. tumor (TCGA) samples. (D) Correlation of PTPN23 expression with immune cell infiltration across cancers. (E) Correlation of PTPN23 expression with Hallmark gene sets and immune pathways. (F) Forest plot of PTPN23 prognostic significance across different cancers. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Fig 8.
Regulation of osteosarcoma cell proliferation by PTPN23.
(A) Absorbance at 450 nm after CCK8 treatment in PTPN23 groups; higher absorbance indicates more cell proliferation. (B) Plate cloning results for SRSF7 treatment groups. (C) Hoechst & EDU staining showing proliferative activity in PTPN23 groups was captured under a 20x (200μm) magnification. (D) Protein expression levels of PTPN23, PCNA, IL-6, STAT3, and p-STAT3 in SJSA-1 and 143B cells from knockdown and control groups. The raw data of the protein bands are stored in S8 Raw images.